Drug Trial Radar · NCT03381274
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
May 8, 2018
Primary completion
May 24, 2021
Study completion Nov 6, 2026
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 101 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
OleclumabBiological
Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.
OsimertinibDrug
Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.
AZD4635Drug
Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicities (DLTs) in Part 1Time frame: From Day 1 to Day 28 after first dose of study drug
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Parts 1 and 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
- Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs in Parts 1 and 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
- Number of Participants With Abnormal Vital Signs and Physical Examination Reported as TEAEs in Parts 1 and 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
- Number of Participants With Notable QTc Interval in Parts 1 and 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
- Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Part 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
San Francisco, California
Research Site
Aurora, Colorado
Research Site
New Haven, Connecticut
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Baltimore, Maryland
Research Site
New York, New York
Research Site
Houston, Texas
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Taichung, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.